WoundReference improves clinical decisions
 Choose the role that best describes you
Zhang Y, Cao W, Xiao M, Li YJ, Yang Y, Zhao J, Zhou X, Jiang W, Zhao YQ, Zhang SY, Li TS, et al.
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. Date of publication 2020 Mar 28;volume 41(0):E006.
1. Zhonghua Xue Ye Xue Za Zhi. 2020 Mar 28;41(0):E006. doi: 10.3760/cma.j.issn.0253-2727.2020.0006. [Epub ahead of print] [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia]. [Article in Chinese; Abstract available in Chinese from the publisher] Zhang Y(1), Cao W(2), Xiao M(3), Li YJ(4), Yang Y(5), Zhao J(6), Zhou X(7), Jiang W(8), Zhao YQ(1), Zhang SY(9), Li TS(2). Author information: (1)Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. (2)Department of Infection Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. (3)Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. (4)Department of General Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. (5)Department of orthopedics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. (6)Department of Respiratory and Critical Care Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. (7)Department of Intensive Care Unit, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. (8)Department of Medical Intensive Care Unit, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. (9)Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. Objective: To investigate the clinical and coagulation characteristics of the critical Coronavirus disease 2019 (COVID-19) patients with acro-ischemia in the intensive care unit (ICU). Methods: The retrospective study included 7 critical COVID-19 patients with acro-ischemia in a single center in Wuhan, from Feb 4 to Feb 15, 2020. The clinical and laboratory data before and during the ICU stay were analyzed. Results: The median age of 7 patients was 59 years and 4 of them were men. 3 of them were associated with underlying comorbidities. Fever, cough, dyspnea and diarrhea were common clinical symptoms. All patients had acro-ischemia presentations including finger/toe cyanosis, skin bulla and dry gangrene. D-dimer, fibrinogen and fibrinogen degradation product (FDP) were significantly elevated in most patients. Prothrombin time (PT) were prolonged in 4 patients. D-dimer and FDP levels increased progressively when COVID-2019 exacerbated, and 4 patients were diagnosed with definite disseminated intravascular coagulation (DIC). 6 patients received low molecular weight heparin (LMWH) treatment, after which their D-dimer and FDP decreased, but there was no significant improvement in clinical symptoms. 5 patients died finally and the median time from acro-ischemia to death was 12 days. Conclusions: The existence of hypercoagulation status in critical COVID-2019 patients should be monitored closely, and anticoagulation therapy can be considered in selected patients. More clinical data is needed to investigate the role of anticoagulation in COVID-2019 treatment. Publisher: 目的: 总结合并肢端缺血的新型冠状病毒肺炎(COVID-19)患者的临床和凝血参数特征。 方法: 回顾性分析2020年2月5日至2020年2月15日,北京协和医院国家医疗队在武汉收治的7例危重型COVID-19患者临床及实验室资料。 结果: 7例患者中男性4例,女性3例,中位年龄59(49~71)岁;3例合并基础病。临床表现为发热7例、干咳6例、呼吸困难4例、腹泻4例。所有患者均存在不同程度的肢端缺血 ,表现为肢端青斑/青紫、血疱、干性坏疽等。7例患者入住重症监护室时均存在D-二聚体显著升高,血小板计数均正常,6例纤维蛋白原升高及纤维蛋白降解产物(FDP)升高, 4例凝血酶原时间(PT)延长。随病情进展,D-二聚体及FDP进行性升高,4例患者符合2017年中国弥散性血管内凝血诊断标准。其中6例患者接受低分子肝素治疗,治疗后 D-二聚体及FDP下降,但临床症状无明显好转。中位随访26天,5例患者死亡,从肢端缺血症状出现至死亡的中位时间为12(7~16)d。 结论: 部分危重型COVID-19患者存在明显高凝倾向,应关注此类患者凝血参数,及时识别高凝期并予抗凝治疗。肢端缺血表现为预后不良提示。抗凝治疗能否改善预后仍需更多临床数 据。. DOI: 10.3760/cma.j.issn.0253-2727.2020.0006 PMID: 32220276
Appears in following Topics:
Cutaneous Manifestations Associated With COVID-19